We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals

215 hedge funds and large institutions have $2.23B invested in Ligand Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 59 increasing their positions, 89 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

146% more call options, than puts

Call options by funds: $23.5M | Put options by funds: $9.54M

138% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 21

29% more capital invested

Capital invested by funds: $1.73B → $2.23B (+$496M)

15% more funds holding

Funds holding: 187215 (+28)

34% less repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 89

40% less funds holding in top 10

Funds holding in top 10: 106 (-4)

Holders
215
Holders Change
+28
Holders Change %
+14.97%
% of All Funds
5.79%
Holding in Top 10
6
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-40%
% of All Funds
0.16%
New
50
Increased
59
Reduced
89
Closed
21
Calls
$23.5M
Puts
$9.54M
Net Calls
+$14M
Net Calls Change
+$14.2M
Name Holding Trade Value Shares
Change
Change in
Stake
AL
76
AJO LP
Pennsylvania
$3.45M +$2.99M +54,807 New
SFP
77
Santa Fe Partners
New Mexico
$3.4M +$2.95M +54,031 New
RCMC
78
RK Capital Management (Colorado)
Colorado
$3.38M -$3.31M -60,594 -53%
California State Teachers Retirement System (CalSTRS)
79
California State Teachers Retirement System (CalSTRS)
California
$3.23M -$350K -6,422 -11%
Susquehanna International Group
80
Susquehanna International Group
Pennsylvania
$3.18M +$1.94M +35,556 +238%
IA
81
Icon Advisers
Colorado
$2.9M -$420K -7,694 -14%
TI
82
Turner Investments
Pennsylvania
$2.83M +$2.45M +44,964 New
New York State Teachers Retirement System (NYSTRS)
83
New York State Teachers Retirement System (NYSTRS)
New York
$2.82M +$8.78K +161 +0.4%
HSBC Holdings
84
HSBC Holdings
United Kingdom
$2.81M -$133K -2,445 -5%
KIA
85
Kopp Investment Advisors
Minnesota
$2.81M +$292K +5,359 +14%
Public Sector Pension Investment Board (PSP Investments)
86
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$2.8M -$525K -9,618 -18%
EI
87
EAM Investors
California
$2.75M -$1.59M -29,064 -40%
VFA
88
Virtus Fund Advisers
Connecticut
$2.74M -$33.1K -607 -1%
AA
89
ALPS Advisors
Colorado
$2.69M +$859K +15,747 +58%
BG
90
BlackRock Group
United Kingdom
$2.68M +$326K +5,979 +16%
TA
91
Teachers Advisors
New York
$2.61M -$292K -5,350 -11%
BCCM
92
Blue Clay Capital Management
Minnesota
$2.59M -$962K -17,633 -30%
UBS Group
93
UBS Group
Switzerland
$2.53M +$175K +3,211 +9%
USAA
94
United Services Automobile Association
Texas
$2.48M +$626K +11,478 +41%
SCM
95
Suffolk Capital Management
New York
$2.48M -$1.57M -28,713 -42%
Millennium Management
96
Millennium Management
New York
$2.18M -$2.7M -49,570 -59%
PP
97
PDT Partners
New York
$2.1M +$91.4K +1,675 +5%
DIA
98
Dana Investment Advisors
Wisconsin
$2.1M +$273K +5,009 +18%
CPA
99
Court Place Advisors
Maryland
$2.09M
RhumbLine Advisers
100
RhumbLine Advisers
Massachusetts
$2.08M -$258K -4,726 -12%

LGND Hedge Fund Activity: Q2 2015 in Review

215 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2015, worth a combined $2.23B — up 29% from $1.73B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new LGND positions and 21 closed out — a net gain of 29 holders — while 59 added to existing stakes and 89 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $32.1M. The largest seller was Goldman Sachs, cutting an estimated $24.1M.

  • 215 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2015, up from 187 in Q1 2015.
  • Funds reported $2.23B of Ligand Pharmaceuticals stock for Q2 2015, up 29% quarter-over-quarter.
  • 50 funds opened new Ligand Pharmaceuticals positions in Q2 2015 and 21 closed out, a net change of +29 holders.
  • The largest Ligand Pharmaceuticals buyer in Q2 2015 was T. Rowe Price Associates, an estimated $32.1M added.
  • The largest Ligand Pharmaceuticals seller in Q2 2015 was Goldman Sachs, an estimated $24.1M sold.

Based on aggregated 13F filings for Q2 2015.